The liver, liver disease, and diabetes mellitus

Endocrinologist

Volumn 13, Issue 1, 2003, Pages 58-66

  Albright, Eric S ^a   Bell, David S H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; GLIBENCLAMIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TROGLITAZONE; ZAFIRLUKAST;

ALCOHOL LIVER CIRRHOSIS; AUTOIMMUNE DISEASE; CANCER INCIDENCE; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DISEASE ASSOCIATION; ENDOCRINE DISEASE; FATTY LIVER; GRANULOMATOUS INFLAMMATION; HEMOCHROMATOSIS; HEPATITIS; HEPATITIS C; HUMAN; HYPERSENSITIVITY; HYPOTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; IRON OVERLOAD; LIVER CARCINOMA; LIVER DISEASE; LIVER TOXICITY; LIVER TRANSPLANTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OBSTRUCTIVE JAUNDICE; PANCREAS ISLET BETA CELL; PREVALENCE; REVIEW; VASCULITIS;

EID: 0037242550     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019616-200301000-00011     Document Type: Review

References (74)

1. Mehta SH, Brancati FL, Sulkowski MS, et al.: Letter: Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Hepatology 2001; 33: 1554.
2. Williams I: Epidemiology of hepatitis C in the United States. Am J Med 1999; 107: 2S-9S.
3. Mehta SH, Brancati FL, Sulkowski MS, et al.: Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133: 592-9.
4. Ryu JK, Lee SB, Hong SJ, et al.: Association of chronic hepatitis C virus infection and diabetes in Korean patients. Korean J Intern Med 2001; 16: 18-23.
5. Ramji A, Yoshida, EM: Diabetes mellitus after liver transplantation: another extra hepatic manifestation of hepatits C. Can J Gastroenterol 2001; 15: 432.
6. Mason AL, Lau JYN, Hoang N, et al.: Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 29: 328-333.
7. Sangiorgio L, Attardo T, Gangemi R, et al.: Increased frequency of HCV and HBV infection in type 2 diabetic patients. Diabetes Res Clin Pract 2000; 48: 147-51.
8. Caronia S, Taylor K, Pagliaro L, et al.: Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 30: 1059-63.
9. Allison MED, Wreghitt T, Palmer CR, et al.: Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 1994; 21: 1135-1139.
10. Strassburg CP, Obermayer-Straaub P, Manns MP: Autoimmunity in hepatitis C and D virus infection. J Viral Hepatitis 1996; 3: 49-59.
11. McCullough, AJ: Update on nonalcoholic fatty liver disease. J Clin Gastroenterol 2002; 34: 255-62.
12. Marchesini G, Brizi M, Bianchi G, et al.: Association of Nonalcoholic Fatty Liver Disease with Insulin Resistance. American J Med 1999; 107: 450-455.
13. Dixon J, Bhathal PS, O'Brien PE: Nonalcoholic fatty liver disease: Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91-100.
14. Reid AE: Nonalcoholic steatohepatitis. Gastroenterology 2001; 121: 710-23.
15. Bernal-Reyes R, Saenz-Labra A, Bernardo-Escudero R: [Prevalence of non-alcoholic steatohepatitis. Comparative study with diabetic patients]. Gastroenterol Mex 2000; 65: 58-62.
16. Valenti L, Fracanzani AL, Dongiovanni Pet al.: Tumor necrosis factor alpha promoter polymorphism and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 274-80.
17. Marchesini G, Brizi M, Bianchi G, et al.: Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-50.
18. Ryysy L, Hakkinen AM, Goto T, et al.: Hepatic fat content and insulin action of free fatty acids and glucose metabolism rather thatn insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000; 49: 749-58.
19. Willner IR, Waters B, Patil SR, et al.: Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastronenterol 2001; 96: 2957-61.
20. Dana SL, Hoener PA, Bilakovics JM, et al.: Peroxisome proliferatior-activated receptor subtype-specific regulation of hepatic and peripheral gene expression in the Zucker diabetic fatty rat. Metabolism 2001; 50: 963-71.
21. Cury D: EASD abstract #A271, Diabetologia 2000 (suppl).
22. Caldwell SH, Hespenheide EE, Redick JA, et al.: A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96: 519-25.
23. Marchesini G, Brizi M, Bianchi G, et al.: Metformin in nonalcoholic steatohepatitis. Lancet 2001; 358: 893-4.
24. Ellervik C, Mandrup-Poulsen T, Nordestgaard BG,et al.: Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study. Lancet 2001; 358: 1405-9.
25. Niederau C, Berger M, Stremmel W, et al.: Hyperinsulinaemia in non-cirrhotic haemochromatosis: impaired hepatic insulin degradation? Diabetologia 1984; 26: 441-4.
26. Turlin B, Mendler MH, Moirand R, et al.: Histologic features of the liver in insulin resistance-associated iron overload. A study of 139 patients. Am J Clin Pathol 2001; 116: 263-70.
27. Kwan T, Leber B, Ahuja S, et al.: Patients with type 2 diabetes have a high frequency of the C282Y mutation of the hemochromatosis gene. Clin Invest Med 1998; 21: 251-7.
28. Sampson MJ, Williams T, Heyburn PH, Greenet al.: Prevelence of HFE (hemochromatosis gene) mutation in unselected male patients with type 2 diabetes. J Lab Clinc Med 2000; 135: 170-3.
29. Frayling T, Ellard S, Grove J, et al.: C282Y mutation in HFE (haemochromatosis) gene and type 2 diabetes. Lancet 1998; 351: 1933-4.
30. Moirand R, Mortaji AM, Loreal O, et al.: A new syndrome of liver iron overload with normal transferring saturation. Lancet 1997; 349: 95-7.
31. Czaja AJ, Carpenter HA, Santarch PJ, et al.: Genetic predispositions for the immunological features of chronic active hepatits. Hepatology 1993; 18: 816.
32. Homberg JC, Abuaf NA, Bernard O, et al.: Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: A second type of "autoimmune" hepatits. Hepatology 1987; 7; 1330-5.
33. Clemente MG, Meloni A, Obermayer-Straub P, et al.: Two Cytochromes P450 are major hepatocellular autoantigens in autoimmune polyglandular syndrome type 1. Gastroenterology 1998; 114: 324-8.
34. Blendis L, Brill S, Oren R: Commentary re: Hepatogenous Diabetes: Reduced insulin sensitivity and increased awareness. Gastroenterology 2000; 119: 1800-2.
35. Shetty A, Wilson S, Kuo P, et al.: Liver transplantation improves cirrhosis-associated impaired oral glucose tolerance. Transplantation 2000; 69: 2451-4.
36. Marchesini G, Bianchi GP, Forlani G, et al.: Insulin resistance is the main determinant of impaired glucose tolerance in patients with liver cirrhosis. Dig Dis Sci 1987; 32: 1118-24.
37. Proietto J, Dudley FJ, Aitken P, et al.: Hyperinsulinaemia and insulin resistance of cirrhosis: the importance of insulin hypersecretion. Clin Endocrinol (Oxf) 1984; 21: 657-65.
38. Sampelean D, Motocu M: Low insulin secretion in decompensated liver cirrhosis with diabetes mellitus. Rom J Intern Med 1993; 31: 265-9.
39. Kruszynska YT, Harry DS, Bergman RN, et al.: Insulin sensitivity, insulin secretion and glucose effectiveness in diabetic and non-diabetic cirrhotic patients. Diabetologia 1993; 36; 121-8.
40. Petrides AS, Schylze-Berge D, Vogt C, et al.: Glucose resistance contributes to diabetes mellitus in cirrhosis. Hepatology 1999; 18: 284-91.
41. Petrides AS, Vogt C, Schulze-Berge D, et al.: Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 1994; 19: 616-27.
42. Perseghin G, Mazzaferro V, Sereni LP, et al.: Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: effect of liver transplantation. Hepatology 2000; 31: 694-703.
43. Merli M, Leonetti F, Riggio O, et al.: Glucose intolerance and insulin resistance in cirrhosis are normalized after liver transplantation. Hepatology 1999; 30: 649-54.
44. Poonawala A, Nair SP, Tuluvath PJ: Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case-control study. Hepatology; 32: 689-92.
45. Pazzi P, Scagliarini R, Gamberini S, et al.: Review Article: gall-bladder motor function in diabetes mellitus. Aliment Pharmacol Ther 2000; 14(Suppl 2): 62-5.
46. Chapman BA, Chapman TM, Frampton CCM, et al.: Gallbladder volume: Comparison of diabetic and controls. Dig Dis Sci 1998; 43: 344-8.
47. De Santis A, Attilit AF, Ginanni Corradini S, et al.: Gallstones and diabetes: A case-control study in a free-living population sample. Hepatology 1997; 25: 787-90.
48. Meguro T, Shimosegawa T, Satoh A, et al.: Gallbladder emptying and cholecystokinin and pancreatic polypeptide responses to a liquid meal in patients with diabetes mellitus. J Gastroenterol 1997; 3295: 628-34.
49. Mitsukawa T, Takermura J, Ohgo S, et al.: Gallbladder function and plasma cholecystokinin levels in diabetes mellitus. Am J Gastroenterol 1990; 85: 981-5.
50. Bedirli A, Sozuer EM, Yuksel O, et al.: Laproscopic cholecystectomy for symptomatic gallstones in diabetic patients. J Laparoendosx Adv Surg Tech 2001; 11: 281-4.
51. Aucott JN, Cooper GS, Bloom AD, et al.: Management of gallstones in diabetic patients. Arch Intern Med 1993; 153: 1053-8.
52. Zein NN, Abdulkarim AS, Wiesner RH, et al.: Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. J Hepatol 2000; 32: 209-17.
53. Adami HO, Chow WH, Nyren O, et al.: Excess risk for primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 1996; 88: 1472-7.
54. El-Serag HB, Richardson PA, Everhart JE: The role of diabetes in hepatocellular carcinoma: A case-control study among United States Veterans. Am J Gastroenterology 2001; 96: 2462-8.
55. Graham DJ, Drinkard CR, Shatin D: Liver enzyme monitoring in patients treated with troglitazone, JAMA 2001; 286: 831-2.
56. Nierenberg DW: "Did this drug cause my patient's hepatitis?" and related questions, Ann Int Med 2002; 136: 480-3.
57. Gouda HE, Khan A, Schwartz j, et al.: Liver failure in a patient treated with long-term rosiglitazone therapy. Am J Med 2001; 111: 584-5.
58. Forman LM, Simmons DA, Diamond RH: Hepatic failure in a patient taking rosiglitazone. Ann Intern Med 2000; 132: 118-21.
59. Al-Salman J, Arjomand H, Kemp DG, et al.: Hepatocellular injury in a patient receiving rosiglitazone. A case report. Ann Intern Med 2000; 132: 121-4. Errata - Al-Salman, et al, Correction: Liver Injury and Rosiglitazone. Ann Intern Med 2000; 133: 237.
60. Maeda K: Letter: Hepatocellular injury in a patient receiving Pioglitazone. Ann Intern Med 2001; 135: 306.
61. May LD, Lefkowitch JH, Kram MT, et al.: Mixed hepatocellularcholestatic liver injury after pioglitazone therapy. Ann Intern Med 2002; 136: 449-52.
62. Lebovitz HE, Kreider M, Freed MI: Evaluation of Liver Function in Type 2 Diabetic Patients During Clinical Trials. Diabetes Care 2002; 25: 815-21.
63. Yamamoto Y, Nakajima M, Yamazaki H, et al.: Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells. Life Sci 2001; 70: 471-82.
64. Sheen AJ: Hepatotoxicity with thiazolidinediones: is it a class effect? Drug Saf 2001; 24: 873-88.
65. Jick SS: Frequency of liver disease in type 2 diabetic patients treated with oral antidiabetic agents. Diabetes Care 1999; 22: 2067-71.
66. Rumboldt Z, Bota B: Favorable effect of glibenclamide in a patient exhibiting idiosyncratic hepatotoxic reactions to both chlorpropamide and tolbutamide. Acta Diabetol Lat 1984; 21: 387-91.
67. Saw D, Pitman E, Maung M, et al.: Granulomatous hepatitis associated with glyburide. Dig Dis Sci 1996; 41: 322-5.
68. Ingelmo M, Vivancos J, Bruguera M, et at.: [Hypersensitivity vasculitis and granulomatous hepatitis induced by glybenclamide: a case report]. Med Clin (Barc) 1980; 75: 306-8.
69. Van Basten JP, van Hoek B, Zeijen R, et al.: Glyburide-induced cholestatic hepatitis and liver failure. Case-report and review of the literature. Neth J Med 1992; 40: 305-7.
70. Andrade RJ, Lucena MI, Rodriguez-Mendizabal M: Letter: Hepatic injury caused by acarbose. Ann Inter Med 1996; 124: 931.
71. Andrade RJ, Lucena M, Vega JL, et at.: Letter: Acarbose-associated heptotoxicity. Diabetes Care 1998; 21: 2029.
72. Fujimoto Y, Ohhira M, Miyokawa N, et al.: Acarbose-induced hepatic injury. Lancet 1998; 351: 340.
73. Carrascosa M, Pascual F, Aresti S: Acarbose-induced acute severe hepatotoxicity. Lancet 1997; 349: 698-9.
74. Mannecier D, Zafrani ES, Dhumeaux D, et al.: [Acarbose-indusce acute hepatitis]. Gastroenterol Clin Biol 1999; 23: 1398-9.